

Marinomed Announces Strategic Expansion into Compounding Services Featuring Marinosolv® Technology

- **Pharmaceutical compounding is a new business opportunity**
- **Marinosolv technology to play key role**
- **First steps initiated**

Korneuburg, Austria, April 22nd, 2026 Marinomed Biotech AG, a healthcare-focused innovator committed to improving patient outcomes, (the "Company") today announced its strategic entry into the compounding business. The company anticipates that several customers will commission services based on the Marinosolv technology in the short to medium term. First revenues are expected in Q4 2026 or beginning of 2027. The company plans to cover its operating costs from its service business. This expansion of its capabilities to deliver customized solutions based on its Marinosolv technology tailored to the evolving needs of customers and partners positions the company to meet growing global demand for customized medicines tailored to individual patient needs, physician preferences, and unmet therapeutic requirements.

By using Marinosolv technology, Marinomed will leverage advanced solubilization capabilities that allow pharmacies a reproducible and standardized process for producing compounded products effectively.

Technologies such as Marinosolv can be especially relevant in:

- Ophthalmic and ENT preparations
- Oral liquid formulations for poorly soluble APIs
- Topical and transdermal applications
- Rapid-onset specialty formulations
- Improved patient-friendly alternatives to conventional dosage forms

"Becoming a solution provider for compounding pharmacies opens an additional, near-term business opportunity for Marinomed. We are convinced that our technology and solutions can provide added value to the daily work of pharmacists and the patients in need of personalized medicines," said Andreas Grassauer, CEO at Marinomed "Our platform allows us to unlock new formulation possibilities and deliver solutions that go beyond the limitations of standard, mass-produced products."

Unlike conventional industrial products, which are manufactured in fixed dosages and standardized formats for broad populations, compounded formulations are tailored to specific patient or physicians' needs. This enables precise dosing and alternative delivery forms (such as liquids, creams, or capsules). As a result, compounded medications can improve adherence, tolerability, and overall outcomes—particularly in cases where commercially available options fall short.

Compounded medications are commonly used in a variety of real-world scenarios, including:

- **Pediatrics:** Creating child-friendly dosage forms, such as flavored liquids, when standard tablets are unsuitable
- **Geriatrics:** Adjusting dosages or forms for patients with swallowing difficulties or complex medication regimens
- **Dermatology:** Preparing personalized topical treatments with specific concentrations or combinations of active ingredients
- **Drug shortages or discontinued products:** Recreating essential medications that are temporarily or permanently unavailable commercially

Key Territories Where Compounding Is Strategically Important

Marinomed intends to prioritize markets where compounding demand is growing and healthcare systems value personalized treatment solutions.

Particularly in German-speaking countries compounding represents a significant part of the business of pharmacies with Germany, Austria, Switzerland (DACH) having strong pharmacy traditions, high regulatory standards, and demand for magistral preparations. In addition, United Kingdom shows a growing need for specialty manufacturing and customized prescriptions as well as Nordics & Benelux – where an advanced healthcare systems supports tailored patient care.

Quality, Compliance, and Strategic Partnerships

Marinomed stated that its compounding operations will be built on robust quality systems, regulatory compliance, validated processes, and partnerships with healthcare professionals, clinics, hospitals, and technology providers.

The company will pursue opportunities in **B2B supply partnerships** while investing in formulation R&D.



About Marinomed Biotech AG

Marinomed Biotech AG is an Austrian, science-based biotech company with a growing development pipeline. The Company develops innovative patent-protected products based on the Marinosolv® platform. The Marinosolv® technology improves the solubility and bioavailability of hardly soluble compounds and is used to develop new therapeutics for autoreactive immune disorders. The Company is headquartered in Korneuburg, Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For further information, please visit: <https://www.marinomed.com>.

For further inquiries contact:

Marinomed Biotech AG

PR: Luca Horinek

IR.: Tobias Meister

T: +43 2262 90300 158

E-Mail: pr@marinomed.com

E-Mail: ir@marinomed.com

Disclaimer

The new shares and subscription rights have not been and will not be registered under foreign securities laws – in particular under the U.S. Securities Act of 1933, as amended ("Securities Act") – with foreign securities authorities and may not be offered or sold, in particular in the United States of America ("US"), without registration or an exemption from the registration requirements under the Securities Act. This communication is not intended for distribution to or within the US and may not be distributed or forwarded to publications with general circulation in the US. This communication constitutes neither an offer to sell nor an invitation to subscribe for or purchase securities in any jurisdiction in which such an offer or such an invitation would be unlawful.